Role of quinupristin/dalfopristin in the treatment of Gram-positive nosocomial infections in haematological or oncological patients

Cancer Treatment Reviews

Volumn 29, Issue 5, 2003, Pages 431-440

  Klastersky, Jean ^a  

^a JULES BORDET INSTITUTE   (Belgium)

Author keywords

Antibiotic resistance; Gram positive; Neutropenic infection; Quinupristin dalfopristin; Streptogramin

Indexed keywords

AMOXICILLIN; AMPHOTERICIN B; ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CEFAMANDOLE; CEFEPIME; CEFTRIAXONE; CEFUROXIME; CIPROFLOXACIN; CISPLATIN; CLINDAMYCIN; CYCLOSPORIN; DALFOPRISTIN PLUS QUINUPRISTIN; DOXYCYCLINE; ERYTHROMYCIN; GENTAMICIN; IMIPENEM; LINCOSAMIDE; MACROLIDE; METICILLIN; MIDAZOLAM; OXACILLIN; PENICILLIN G; POLYPEPTIDE ANTIBIOTIC AGENT; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SPARFLOXACIN; STREPTOGRAMIN; TEICOPLANIN; UNINDEXED DRUG; VANCOMYCIN;

ALPHA HEMOLYTIC STREPTOCOCCUS; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTHRALGIA; BACTEREMIA; BACTERIAL INFECTION; BACTERIUM ISOLATE; CANCER PATIENT; CATHETER INFECTION; COAGULASE NEGATIVE STAPHYLOCOCCUS; DIARRHEA; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG METABOLISM; DRUG PENETRATION; DRUG SAFETY; DRUG SENSITIVITY; DRUG TOLERABILITY; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; GRAM POSITIVE BACTERIUM; HOSPITAL INFECTION; HUMAN; IN VITRO STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MULTIDRUG RESISTANCE; MYALGIA; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; NONHUMAN; OTOTOXICITY; PATHOGENESIS; RASH; REVIEW; STAPHYLOCOCCUS AUREUS; VOMITING;

EID: 0141502360     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0305-7372(03)00069-0     Document Type: Article

References (85)

1. Hughes WT, Armstrong D, Bodey GP, et al. 1997 guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Clin Infect Dis 1997; 25: 551-573.
2. Klastersky J. Science and pragmatism in the treatment and prevention of neutropenic infection. J Antimicrob Chemother 1998; 41(Suppl D): 13-24.
3. Oppenheim BA. The changing pattern of infection in neutropenic patients. J Antimicrob Chemother 1998; 41(Suppl D): 7-11.
4. Jones RN, Low DE, Pfaller MA. Epidemiologic trends in nosocomial and community-acquired infections due to antibiotic-resistant Gram-positive bacteria: the role of streptogramins and other newer compounds. Diagn Microbiol Infect Dis 1999; 33: 101-112.
5. Cometta A, Calandra T, Gaya H, et al. Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. Antimicrob Agents Chemother 1996; 40: 1108-1115.
6. González-Barca E, Fernández-Sevilla A, Carratalá J, Granena A, Gudiol F. Prospective study of 288 episodes of bacteremia in neutropenic cancer patients in a single institution. Eur J Clin Microbiol Infect Dis 1996; 15: 291-296.
7. Pfaller MA, Jones RN, Doern GV, Kugler K and the SENTRY Participants Group. Bacterial pathogens isolated from patients with bloodstream infection: frequencies of occurrence and antimicrobial susceptibility patterns from the SENTRY antimicrobial surveillance program (United States and Canada, 1997). Antimicrob Agents Chemother 1998; 42: 1762-1770.
8. Elting LS, Rubenstein EB, Rolston KVI, Bodley GP. Outcomes of bacteremia in patients with cancer and neutropenia: observations from two decades of epidemiological and clinical trials. Clin Infect Dis 1997; 25: 247-259.
9. Bochud PY, Eggiman P, Calandra T, Van Melle G, Saghafi L, Francioli P. Bacteremia due to viridans streptococcus in neutropenic patients with cancer: clinical spectrum and risk factors. Clin Infect Dis 1994; 18: 25-31.
10. Dugdale DC, Ramsey PG. Staphylococcus aureus bacteremia in patients with Hickman catheters. Am J Med 1990; 89: 137-141.
11. Kiehn TE, Armstrong D. Changes in the spectrum of organisms causing bacteremia and fungemia in immunocompromised patients due to venous access devices. Eur J Clin Microbiol Infect Dis 1990; 9: 869-872.
12. Rubio M, Palau L, Vivas JR, et al. Predominance of Gram-positive microorganisms as a cause of septicemia in patients with hematological malignancies. Infect Control Hosp Epidemiol 1994; 15: 101-104.
13. Kibbler CC. Neutropenic infections: strategies for empiric therapy. J Antimicrob Chemother 1995; 36(Suppl B): 107-117.
14. Jones RN, Ballow CH, Biedenbach DJ, Deinhart JA, Schentag JJ. Antimicrobial activity of quinupristin-dalfopristin (RP 59500, Synercid) tested against over 28,000 recent clinical isolates from 200 medical centers in the United States and Canada. Diagn Microbiol Infect Dis 1998; 30: 437-451.
15. Schmitz F-J, Verhoef J, Fluit AC and the Sentry Participants Group. Prevalence of resistance to MLS antibiotics in 20 European university hospitals participating in the European SENTRY surveillance programme. J Antimicrob Chemother 1999; 43: 783-792.
16. Fluit AC, Jones ME, Schmitz FJ, Acar J, Gupta R, Verhoef J. Antimicrobial susceptibility and frequency of occurrence of clinical blood isolates in Europe from the SENTRY antimicrobial surveillance program, 1997 and 1998. Clin Infect Dis 2000; 30: 454-460.
17. Gordon KA, Beach ML, Biedenbach DJ, Jones RN, Rhomberg PR, Mutnick AH. Antimicrobial susceptibility patterns of β-hemolytic and viridans group streptococci: report from the SENTRY Antimicrobial Surveillance Program (1997-2000). Diagn Microbiol Infect Dis 2002; 43: 157-162.
18. Lewis MT, Jones RN. Activity of macrolides, lincosamines, streptogramins and fluoroquinolones against Streptococcus pneumoniae and Enterococci isolates from the Western Hemisphere: example of International Surveillance (SENTRY Antimicrobial Surveillance Program) in the development of new drugs. Braz J Infect Dis 2000; 4: 15-21.
19. Archer GL. Staphylococcus aureus: a well-armed pathogen. Clin Infect Dis 1998; 26: 1179-1181.
20. Witte W. Antibiotic resistance in Gram-positive bacteria: epidemiological aspects. J Antimicrob Chemother 1999; 44(Topic A): 1-9.
21. Von Eiff C, Reinert RR, Kresken M, Brauers J, Hafner D, Peters G. Nationwide German multicenter study on prevalence of antibiotic resistance in Staphylococcal bloodstream isolates and comparative in vitro activities of quinupristin-dalfopristin. J Clin Microbiol 2000; 38: 2819-2823.
22. Marshall SA, Wilke WW, Pfaller MA, Jones RN. Staphylococcus aureus and coagulase-negative staphylococci from bloodstream infections: frequency of occurrence, antimicrobial susceptibility, and molecular (mec A) characterization of oxacillin resistance in the SCOPE Program. Diagn Microbiol Infect Dis 1998; 30: 205-214.
23. Archer GL, Climo MW. Antimicrobial susceptibility of coagulase-negative staphylococci. Antimicrob Agents Chemother 1994; 38: 2231-2237.
24. Doern GV, Ferraro MJ, Brueggemann AB, Ruoff KL. Emergence of high rates of antimicrobial resistance among viridans group streptococci in the United States. Antimicrob Agents Chemother 1996; 40: 891-894.
25. Evans PA, Norden CW, Rhoads S, Deobaldia J, Silber JL. In vitro susceptibilities of clinical isolates of vancomycin-resistant enterococci. Antimicrob Agents Chemother 1997; 41: 1406.
26. Tripodi MF, Attanasio V, Adinolfi LE, et al. Prevalence of antibiotic resistance among clinical isolates of methicillin-resistant staphylococci. Eur J Clin Microbiol Infect Dis 1994; 13: 148-152.
27. Sieradzki K, Villari P, Tomasz A. Decreased susceptibilities to teicoplanin and vancomycin among coagulase-negative methicillin-resistant clinical isolates of staphylococci. Antimicrob Agents Chemother 1998; 42: 100-107.
28. Del' Alamo L, Cereda RF, Tosin I, Miranda EA, Sader HS. Antimicrobial susceptibility of coagulase-negative staphylococci and characterization of isolates with reduced susceptibility to glycopeptides. Diagn Microbiol Infect Dis 1999; 34: 185-191.
29. Hiramatsu K, Hanaki H, Ino T, Yabuta K, Oguri T, Tenover FC. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother 1997; 40: 135-136.
30. Geisel R, Schmitz F-J, Thomas L, et al. Emergence of heterogenous intermediate vancomycin resistance in Staphylococcus aureus isolates in the Düsseldorf area. J Antimicrob Chemother 1999; 43: 846-848.
31. Sieradzki K, Roberts RB, Haber SW, Tomasz A. The development of vancomycin resistance in a patient with methicillin-resistant Staphylococcus aureus infection. N Engl J Med 1999; 340: 517-523.
32. Smith TL, Pearson ML, Wilcox KR, et al. Emergence of vancomycin resistance in Staphylococcus aureus. N Engl J Med 1999; 340: 493-501.
33. Tenover FC, Lancaster MV, Hill BC, et al. Characterization of staphylococci with reduced susceptibilities to vancomycin and other glycopeptides. J Clin Microbiol 1998; 36: 1020-1027.
34. Noble WC, Virani Z, Cree RGA. Co-transfer of vancomycin and other resistance genes from Enterococcus faecalis NCTC 12201 to Staphylococcus aureus. FEMS Microbiol Lett 1992; 93: 195-198.
35. Daschner FD, Kropec A. Glycopeptides in the treatment of staphylococcal infections. Eur J Clin Microbiol Infect Dis 1995; 14(Suppl 1): S12-S17.
36. Hamilton-Miller JMT, Shah S. Activity of quinupristin/dalfopristin against Staphylococcus epidermidis in biofilms: a comparison with ciprofloxacin. J Antimicrob Chemother 1997; 39(Suppl A): 103-108.
37. Wood MJ. The comparative efficacy and safety of teicoplanin and vancomycin. J Antimicrob Chemother 1996; 37: 209-222.
38. Zeckel ML. A closer look at vancomycin, teicoplanin, and antimicrobial resistance. J Chemother 1997; 9: 311-335.
39. EORTC International Antimicrobial Therapy Cooperative Group and the National Cancer Institute of Canada-Clinical Trials Group. Vancomycin added to empirical combination antibiotic therapy for fever in granulocytopenic cancer patients. J Infect Dis 1991; 163: 951-958.
40. Bryson HM, Spencer CM. Quinupristin-dalfopristin. Drugs 1996; 52: 406-415.
41. Aumercier M, Bouhallab S, Capmau ML, Le Goffic F. RP 59500: a proposed mechanism for its bactericidal activity. J Antimicrob Chemother 1992; 30(Suppl A): 9-14.
42. Cocito C, Di Giambattista M, Nyssen E, Vannuffel P. Inhibition of protein synthesis by streptogramins and related antibiotics. J Antimicrob Chemother 1997; 39(Suppl A): 7-13.
43. Bouanchaud DH. In-vitro and in-vivo antibacterial activity of quinupristin-dalfopristin. J Antimicrob Chemother 1997; 39(Suppl A): 15-21.
44. Dowzicky M, Nadler HL, Feger C, Talbot GH, Bompart F, Pease M. Evaluation of in vitro activity of quinupristin/dalfopristin (Q/D) and comparator antimicrobial agents against worldwide clinical trial and other laboratory isolates. Am J Med 1998; 104(5A): 34S-42S.
45. National Committee for Clinical Laboratory Standards (NCCLS). Subcommittee on Antimicrobial Susceptibility Testing. Minutes of June 1998 meeting. Reston, Villanova, USA.
46. Andrews J, Ashby J, Jevons G, Lines N, Wise R. Antimicrobial resistance in Gram-positive pathogens isolated in the UK between October 1996 and January 1997. J Antimicrob Chemother 1999; 43: 689-698.
47. Cohen MA, Huband MD. Activity of clinafloxacin, trovafloxacin, quinupristin/dalfopristin, and other antimicrobial agents versus Staphylococcus aureus isolates with reduced susceptibility to vancomycin. Diagn Microbiol Infect Dis 1999; 33: 43-46.
48. Low DE, Keller N, Barth A, Jones RN. Clinical prevalence, antimicrobial susceptibility, and geographic patterns of enterococci: results from the SENTRY Antimicrobial Surveillance Program, 1997-1999. Clin Infect Dis 2001; 32: S133-S145.
49. Desnottes JF, Diallo N. Cellular uptake and intracellular bactericidal activity of RP 59500 in murine macrophages. J Antimicrob Chemother 1992; 30(Suppl A): 107-115.
50. Berthaud N, Desnottes J-F. In-vitro bactericidal activity of quinupristin/dalfopristin against adherent Staphylococcus aureus. J Antimicrob Chemother 1997; 39(Suppl A): 99-102.
51. Berthaud N, Huet Y, Diallo N, Desnottes JF. Antistaphylococcal activities of quinupristin/dalfopristin in vitro across platelet-fibrin matrices and in experimental endocarditis. J Antimicrob Chemother 1997; 39(Suppl A): 93-98.
52. Fass RJ. In vitro activity of RP 59500, a semisynthetic injectable pristinamycin, against staphylococci, streptococci, and enterococci. Antimicrob Agents Chemother 1991; 35: 553-559.
53. Verbist L, Verhaegen J. Comparative in-vitro activity of RP 59500. J Antimicrob Chemother 1992; 30(Suppl A): 39-44.
54. Hoban DJ, Weshnoweski B, Palatnick L, Zhanel CG, Davidson RJ. In-vitro activity of streptogramin RP 59500 against staphylococci, including bactericidal kinetic studies. J Antimicrob Chemother 1992; 30(Suppl A): 59-65.
55. Shonekan D, Handwerger S, Mildvan D. Comparative in-vitro activities of RP 59500 (quinupristin/dalfopristin), CL 329,998, Cl 331,002, trovafloxacin, clinafloxacin, teicoplanin and vancomycin against Gram-positive bacteria. J Antimicrob Chemother 1997; 39: 405-409.
56. Entenza JM, Drugeon H, Glauser MP, Moreillon P. Treatment of experimental endocarditis due to erythromycin-susceptible or -resistant methicillin-resistant Staphylococcus aureus with RP 59500. Antimicrob Agents Chemother 1995; 39: 1419-1424.
57. Fantin B, Leclercq R, Merle Y, et al. Critical influence of resistance to streptogramin B-type antibiotics on activity of RP 59500 (quinupristin-dalfopristin) in experimental endocarditis due to Staphylococcus aureus. Antimicrob Agents Chemother 1995; 39: 400-405.
58. Caron F, Gold HS, Wennersten CB, Farris MG, Moellering Jr RC, Eliopoulos GM. Influence of erythromycin resistance, inoculum growth phase, and incubation time on assessment of the bactericidal activity of RP 59500 (quinupristin-dalfopristin) against vancomycin-resistant Enterococcus faecium. Antimicrob Agents Chemother 1997; 41: 2749-2753.
59. Brumfitt W, Hamilton-Miller JMT, Shah S. In-vitro activity of RP 59500, a new semisynthetic streptogramin antibiotic, against Gram-positive bacteria. J Antimicrob Chemother 1992; 30(Suppl A): 29-37.
60. Neu HC, Chin N-X, Gu J-W. The in-vitro activity of new streptogramins, RP 59500, RP 57669 and RP 54476, alone and in combination. J Antimicrob Chemother 1992; 30(Suppl A): 83-94.
61. Leclercq R, Nantas L, Soussy C-J, Duval J. Activity of RP 59500, a new parenteral semisynthetic streptogramin, against staphylococci with various mechanisms of resistance to macrolide-lincosamide, streptogramin antibiotics. J Antimicrob Chemother 1992; 30(Suppl A): 67-75.
62. Low DE, Nadler HL. A review of in-vitro antibacterial activity of quinupristin-dalfopristin against methicillin-susceptible and -resistant Staphylococcus aureus. J Antimicrob Chemother 1997; 39(Suppl A): 53-58.
63. Kostman JR, Fekete T, Woodwell J. Emergence of macrolide-streptogramin resistance during therapy of Staphylococcus aureus bacteremia with quinupristin/dalfopristin (RP59500). Clin Infect Dis 1995; 21: 746, Abstract.
64. Chow JW, Donabedian SM, Zervos MJ. Emergence of increased resistance to quinupristin/dalfopristin during therapy for Enterococcus faecium bacteremia. Brief report. Clin Infect Dis 1997; 24: 90-91.
65. Dowzicky M, Talbot GH, Feger C, Prokocimer P, Etienne J, Leclercq R. Characterization of isolates associated with emerging resistance to quinupristin/dalfopristin (Synercid) during a worldwide clinical program. Diagn Microbiol Infect Dis 2000; 37: 57-62.
66. Fantin B, Leclercq R, Garry L, Carbon C. Influence of inducible cross-resistance to macrolides, lincosamides, and streptogramin B-type antibiotics in Enterococcus faecium on activity of quinupristin dalfopristin in vitro and in rabbits with experimental endocarditis. Antimicrob Agents Chemother 1997; 41: 931-935.
67. Aeschlimann JR, Zervos MJ, Rybak MJ. Treatment of vancomycin-resistant Enterococcus faecium with RP 59500 (quinupristin-dalfopristin) administered by intermittent or continuous infusion, alone or in combination with doxycycline, in an in vitro model with simulated endocardial vegetations. Antimicrob Agents Chemother 1998; 42: 2710-2717.
68. Vouillamoz J, Entenza JM, Giddey M, Glauser MP, Moreillon P. In vitro efficacy of Synercid (quinupristin/dalfopristin) (SYN) combined with other classes of antibiotics against methicillin susceptible and resistant Staphylococcus aureus (MSSA and MRSA). Presented at the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), 1996.
69. B-resistant). Presented at the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), 1998.
70. Chin NX, Neu HC. Post-antibiotic effect of the new streptogramin RP 59500. Eur J Clin Microbiol Infect Dis 1992; 11: 642-645.
71. Boswell FJ, Andrews JM, Wise R. The postantibiotic effect of RP 59500 on Staphylococcus aureus including strains with a raised MBC. J Antimicrob Chemother 1994; 33: 1219-1222.
72. Nougayrede A, Berthaud N, Bouanchaud DH. Postantibiotic effects of RP 59500 with Staphylococcus aureus. J Antimicrob Chemother 1992; 30(Suppl A): 101-106.
73. Craig W, Ebert S. Pharmacodynamic activities of RP 59500 in an animal infection model. In: Program and Abstracts of the thirty-third Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), New Orleans, 17-20 October 1993. Abstract p. 205. American Society for Microbiology, Washington, DC.
74. Bergeron M, Montay G. The pharmacokinetics of quinupristin/dalfopristin in laboratory animals and in humans. J Antimicrob Chemother 1997; 39(Suppl A): 129-138.
75. Rubinstein E, Prokocimer P, Talbot GH. Safety and tolerability of quinupristin/dalfopristin: administration guidelines. J Antimicrob Chemother 1999; 44(Topic A): 37-46.
76. Chambers HF. Studies of RP 59500 in vitro and in a rabbit model of aortic valve endocarditis caused by methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother 1992; 30(Suppl A): 117-122.
77. Fantin B, Leclercq R, Ottaviani M, et al. In vivo activities and penetration of the two components of the streptogramin RP 59500 in cardiac vegetations of experimental endocarditis. Antimicrob Agents Chemother 1994; 38: 432-437.
78. L'Hériteau F, Entenza JM, Lacassin F, Leport C, Glauser MP, Moreillon P. RP 59500 prophylaxis of experimental endocarditis due to erythromycin-susceptible and -resistant isogenic pairs of viridans group streptococci. Antimicrob Agents Chemother 1995; 39: 1425-1429.
79. Berthaud N, Montay G, Conard BJ, Desnottes JF. Bactericidal activity and kinetics of RP 59500 in a mouse model of Staphylococcus aureus septicemia. J Antimicrob Chemother 1995; 36: 365-373.
80. Finch RG. Antibacterial activity of quinupristin/dalfopristin. Rationale for clinical use. Drugs 1996; 51(Suppl 1): 31-37.
81. Raad I, Bompart F, Hachem R. Prospective, randomized dose-ranging open phase II pilot study of quinupristin/dalfopristin versus vancomycin in the treatment of catheter-related staphylococcal bacteremia. Eur J Clin Microbiol Infect Dis 1999; 18: 199-202.
82. Talbot GH, Barriere S, Cerwinka S, et al. Efficacy of quinupristin/dalfopristin (Synercid, RP 59500) in the treatment of patients with positive blood cultures in global phase III studies. In Abstracts/Posters Presented at the 20th International Congress of Chemotherapy (ICC), Sydney, Australia, June 29-July 3, 1997.
83. Nichols RL, Graham DR, Barriere SL, et al. for the Synercid Skin and Skin Structure Infection Group. Treatment of hospitalized patients with complicated Gram-positive skin and skin structure infections: two randomized, multicentre studies of quinupristin/dalfopristin versus cefazolin, oxacillin or vancomycin. J Antimicrob Chemother 1999; 44: 263-273.
84. Moellering RC, Linden PK, Reinhardt J, Blumberg EA, Bompart F, Talbot GH for the Synercid Emergency-Use Study Group. The efficacy and safety of quinupristin/dalfopristin for the treatment of infections caused by vancomycin-resistant Enterococcus faecium. J Antimicrob Chemother 1999; 44: 251-261.
85. Srinath L, Feger C, Richard M-P, Prokocimer P, Gray SL. Efficacy and safety of quinupristin/dalfopristin (Synercid) for treatment of methicillin-resistant Staphylococcus aureus infections. In Abstracts/Posters Presented at the 5th International Conference on the macrolides, azalides, streptogramins, ketolides and oxazolidinones (ICMAS-KO), Seville, Spain, January 26-28, 2000.